MARKET

RCOR-WS

RCOR-WS

Renovacor Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

0.0701
0.00
0.00%
Opening 09:30 06/29 EDT
OPEN
--
PREV CLOSE
0.0701
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.9800
52 WEEK LOW
0.0536
MARKET CAP
--
P/E (TTM)
-0.0737
1D
5D
1M
3M
1Y
5Y
BRIEF-Renovacor Says Fred Driscoll, Co's CFO And Corporate Secretary Notified Co Of His Decision To Resign Effective As Of June 17, 2022
reuters.com · 06/03 20:27
BRIEF-Renovacor Announces Data From Pilot Pig Study Showing Successful Cardiac Transduction With REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion
reuters.com · 06/01 20:14
BRIEF-Renovacor Announces Appointment Of Fred Driscoll As CFO
reuters.com · 03/28 11:35
BRIEF-Renovacor Reports Fourth Quarter And Full Year 2021 Results
reuters.com · 03/24 21:24
BRIEF-Renovacor Names Elizabeth White As Chief Business Officer And Senior Vice President Of Operations
reuters.com · 07/19/2021 12:40
BRIEF-Renovacor Inc To Merge With Chardan Healthcare Acquisition 2 Corp
reuters.com · 03/23/2021 12:03
No Data
Learn about the latest financial forecast of RCOR-WS. Analyze the recent business situations of Renovacor Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.54%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/President/Chief Executive Officer/Director
Magdalene Cook
Chief Financial Officer
Wendy DiCicco
Senior Vice President
Elizabeth White
Chief Scientific Officer
Matthew Killeen
Other
Marc Semigran
Other
Jiwen Zhang
Independent Director
Gbola Amusa
Independent Director
Edward Benz
Independent Director
Gregory Covino
Independent Director
Jonas Grossman
Independent Director
Joan Lau
Independent Director
Thomas Needham
No Data
No Data
About RCOR-WS
Renovacor, Inc., formerly Chardan Healthcare Acquisition 2 Corp., is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. It focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy. Its lead product candidate, REN-001, is an AAV9-based gene therapy designed to treat BAG3-associated dilated cardiomyopathy (DCM).

Webull offers kinds of Renovacor Inc stock information, including AMEX:RCOR WS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCOR WS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCOR-WS stock methods without spending real money on the virtual paper trading platform.